Paion

About:

PAION is a biopharmaceutical company developing and commercializing drug candidates for diseases with substantial unmet medical needs.

Website: http://www.paion.com

Twitter/X: paionag

Top Investors: Reference Capital SA

Description:

PAION AG, together with its subsidiaries, operates as a biopharmaceutical company that engages in developing and commercializing drug candidates for diseases or interventions with a substantial unmet medical need. The company’s lead compound is remimazolam, an intravenous, ultra-short-acting, and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside. The product can be used for general anesthesia in Europe and procedural sedation in the United States. It was founded in 2000 and is based in Aachen, Nordrhein-Westfalen, Germany.

Total Funding Amount:

$41.1M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Aachen, Nordrhein-Westfalen, Germany

Founded Date:

2000-01-01

Contact Email:

info(AT)paion.com

Founders:

Mariola Söhngen, Wolfgang Söhngen

Number of Employees:

11-50

Last Funding Date:

2018-07-03

IPO Status:

Public

Industries:

© 2025 bioDAO.ai